- Home
- OTLK vs HGBL Comparison
OTLK vs HGBL Comparison
Compare OTLK & HGBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- HGBL
- Stock Information
- Founded
- OTLK 2010
- HGBL 1937
- Country
- OTLK United States
- HGBL United States
- Employees
- OTLK N/A
- HGBL N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- HGBL Business Services
- Sector
- OTLK Health Care
- HGBL Consumer Discretionary
- Exchange
- OTLK Nasdaq
- HGBL Nasdaq
- Market Cap
- OTLK 42.8M
- HGBL 51.1M
- IPO Year
- OTLK 2016
- HGBL N/A
- Fundamental
- Price
- OTLK $1.69
- HGBL $1.36
- Analyst Decision
- OTLK Buy
- HGBL Strong Buy
- Analyst Count
- OTLK 5
- HGBL 1
- Target Price
- OTLK $5.25
- HGBL $4.00
- AVG Volume (30 Days)
- OTLK 4.5M
- HGBL 92.1K
- Earning Date
- OTLK 12-26-2025
- HGBL 11-06-2025
- Dividend Yield
- OTLK N/A
- HGBL N/A
- EPS Growth
- OTLK N/A
- HGBL N/A
- EPS
- OTLK N/A
- HGBL 0.09
- Revenue
- OTLK $1,505,322.00
- HGBL $49,890,000.00
- Revenue This Year
- OTLK N/A
- HGBL $20.86
- Revenue Next Year
- OTLK $342.80
- HGBL $4.61
- P/E Ratio
- OTLK N/A
- HGBL $15.49
- Revenue Growth
- OTLK N/A
- HGBL 0.02
- 52 Week Low
- OTLK $0.79
- HGBL $1.21
- 52 Week High
- OTLK $5.18
- HGBL $2.39
- Technical
- Relative Strength Index (RSI)
- OTLK 59.10
- HGBL 49.17
- Support Level
- OTLK $1.76
- HGBL $1.28
- Resistance Level
- OTLK $2.02
- HGBL $1.37
- Average True Range (ATR)
- OTLK 0.20
- HGBL 0.08
- MACD
- OTLK 0.04
- HGBL 0.02
- Stochastic Oscillator
- OTLK 59.38
- HGBL 65.38
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About HGBL Heritage Global Inc.
Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.